Advances in Small Molecule Drugs Targeting PD-1/PD-L1 PD-1/L1 antibodies can be said to be the current hot direction in the development of targeted cancer drugs. However, monoclonal antibodies have many inherent drawbacks, including poor oral bioavailability, prolonged tissue retention time and half-life, poor membrane permeability, transportation and storage, etc. In addition, the high cost of antibody drugs is also a non-negligible problem. Therefore, more and more researchers are exploring small molecule drugs as PD-1/L1 inhibitors to circumvent the disadvantages of therapeutic antibodies.
1 Vote
Created
Robin jack at November 24, 2024 at 3:07am MST
Magnificent goods from you, man. I’ve understand your stuff previous to and you’re just extremely great. I really like what you’ve acquired here, really like what you are saying and the way in which you say it. You make it enjoyable and you still take care of to keep it wise. I can not wait to read much more from you. This is really a tremendous website. 온포커 홀덤사이트
Robin jack at November 24, 2024 at 5:27am MST
I loved as much as you’ll receive carried out right here. The sketch is attractive, your authored subject matter stylish. nonetheless, you command get bought an impatience over that you wish be delivering the following. unwell unquestionably come further formerly again since exactly the same nearly a lot often inside case you shield this increase. 홀덤사이트 추천 GG홀덤